These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11111145)

  • 1. Effects of intracoronary tissue-type plasminogen activator treatment in kawasaki disease and acute myocardial infarction.
    Nakagawa M; Watanabe N; Okuno M; Okamoto N; Fujino H
    Cardiology; 2000; 94(1):52-7. PubMed ID: 11111145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease.
    Horigome H; Sekijima T; Miyamoto T
    Heart; 1997 Nov; 78(5):517-8. PubMed ID: 9415017
    [No Abstract]   [Full Text] [Related]  

  • 3. Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction.
    Katayama F; Hiraishi S; Takeda N; Misawa H
    Heart; 1997 Dec; 78(6):621-2. PubMed ID: 9470886
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi].
    Ichinose E; Kato H; Inoue O; Hirata K; Eto Y; Yoshioka F
    J Cardiogr; 1985 Mar; 15(1):79-87. PubMed ID: 4067350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic therapy in Kawasaki disease: a report of four cases.
    Harada M; Akimoto K; Otaka M; Sato K; Oda H; Otsuki M; Takahashi K; Kishiro M; Shimizu T
    Pediatr Int; 2013 Oct; 55(5):e111-5. PubMed ID: 24134762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
    Kato H; Inoue O; Ichinose E; Akagi T; Sato N
    Acta Paediatr Jpn; 1991 Feb; 33(1):27-35. PubMed ID: 1853711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease.
    Tsubata S; Ichida F; Hamamichi Y; Miyazaki A; Hashimoto I; Okada T
    Pediatr Cardiol; 1995; 16(4):186-9. PubMed ID: 7567665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient Q-waves in an infant with asymptomatic myocardial infarction due to Kawasaki disease.
    Akagawa D; Motoki N; Hachiya A; Akazawa Y
    Cardiol Young; 2019 Feb; 29(2):231-234. PubMed ID: 30520707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease complicated by cerebral infarction.
    Suda K; Matsumura M; Ohta S
    Cardiol Young; 2003 Feb; 13(1):103-5. PubMed ID: 12691296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of myocardial infarction in children with Kawasaki disease.
    Paredes N; Mondal T; Brandão LR; Chan AK
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):620-31. PubMed ID: 20717006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary recombinant tissue-type plasminogen activator (rt-PA).
    Tiefenbrunn AJ
    Coron Artery Dis; 1996 Sep; 7(9):637-40. PubMed ID: 8950493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Six Kawasaki disease patients with acute coronary artery thrombosis].
    Zhou SL; Luo JP; Qi YQ; Liang YG; Wang W; Gong FQ
    Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):925-9. PubMed ID: 24495764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
    Jone PN; Tapia D; Davidson J; Fagan TE; Browne L; Ing RJ; Kay J
    Semin Cardiothorac Vasc Anesth; 2015 Sep; 19(3):255-9. PubMed ID: 25700695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recanalization characteristics of intracoronary streptokinase compared to intravenous tissue plasminogen activator following acute myocardial infarction: a community hospital experience.
    Ramos RS; Salem BI; Gowda S; Haikal M; Coordes C; Leidenfrost R
    South Med J; 1995 Sep; 88(9):947-52. PubMed ID: 7660214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator: intracoronary applications.
    Tiefenbrunn AJ
    Cathet Cardiovasc Diagn; 1990 Feb; 19(2):108-15. PubMed ID: 2106393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture].
    Sakai M; Imai T; Kuboki K; Maeda S; Ueda S; Kuwajima I; Ohkawa S; Matsushita S
    J Cardiol; 1999 Mar; 33(3):153-61. PubMed ID: 10225195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase.
    Kelly RV; Crouch E; Krumnacher H; Cohen MG; Stouffer GA
    Catheter Cardiovasc Interv; 2005 Nov; 66(3):327-32. PubMed ID: 16208711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator in pediatric myocardial infarction.
    Krendel S; Pollack P; Hanly J
    Ann Emerg Med; 2000 May; 35(5):502-5. PubMed ID: 10783412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
    Motomiya T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
    [No Abstract]   [Full Text] [Related]  

  • 20. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.